Reach-2 Trial Design: A Phase 3, Randomized, Open-Label, Multicenter Study to Evaluate Ruxolitinib Compared to Best Available Therapy in Patients with Corticosteroid-Refractory Acute Graft vs Host Disease after Allogeneic Stem Cell Transplantation

著录项

• 来源
  《Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation》 |2018年第3期|共1页
• 作者

  Gérard Socié; Dietger Niederwieser; Nikolas von Bubnoff; Jeff Szer; Mohamad Mohty; Mary Laughlin; Betty Molloy; Leslie OSullivan-Djentuh; Robert Zeiser;

  展开▼
• 作者单位

  APHP Hématologie-Transplantation H?pital St Louis Université Denis Diderot and INSERM UMR 1160;

  Department of Hematology and Oncology University of Leipzig;

  Department of Hematology Oncology and Stem Cell Transplantation Medical Center University of;

  Royal Melbourne Hospital;

  Hopital Saint-Antoine;

  Novartis Pharmaceuticals Corporation;

  Novartis Pharma AG;

  Novartis Pharma AG;

  Department of Hematology Oncology and Stem Cell Transplantation University Hospital Freiburg;

  展开▼
• 收录信息
• 原文格式 PDF
• 正文语种 eng
• 中图分类 治疗学;
• 关键词